WASHINGTON, DC – HOST CITY FOR 2005 ANNUAL MEETING

Washington, DC is the host city for the 24th Symposium to be held June 19-23, 2005 at the JW Marriott hotel.

Not only is it the nation's capital and the cradle of American government, Washington, DC also represents a culmination of historical sites with over 60 museums (including the newly opened: National Museum of the American Indian), monuments (including the recently completed World War II Monument), cultural diversity, a rich performing arts community (that includes more theatrical performances each year than any American city outside of New York City and one of the world's 3 great Shakespearean theaters), and a lively night life with restaurants that highlight over 50 ethnic cuisines.

Washington, DC is located in the center of the Atlantic seaboard, nestled between Maryland and Virginia. Washington, DC's weather in June has low humidity and agreeable climate for exploring its outdoor treasures. Whether one is site seeing, taking pedal boats on the Tidal Basin, jogging or kayaking on the Potomac River, or picnicing on The Mall, Washington, DC has something for everyone.

ANNUAL MEETING PROGRAM

CARDIOVASCULAR TOXICOLOGIC PATHOLOGY: SAFETY ASSESSMENT AND RISK MANAGEMENT
JUNE 19-23, 2005

The focus of the scientific program of the 2005 Society of Toxicologic Pathology Annual Meeting is the cardiovascular system with a special emphasis on safety assessment and risk management. The information presented in each session will be comprehensive and include critical reviews of current animal models to identify and characterize potential safety concerns based on mechanistic approaches (including current, often well publicized, examples) along with management of such potential risks. The individual session chairmen have done an excellent job in collecting a diverse group of speakers who are leaders in their field. These speakers will be presenting from the perspective of regulatory agencies, the pharmaceutical industry and academia in order to allow attendees to gain a broad holistic knowledge of the current issues and how potential liabilities can and have been put into perspective and managed. In addition to traditional toxicologic pathology topics concerning the vascular and cardiac systems, this year's scientific program will include sessions on the evolving and increasingly important topics of drug eluting stents and other devices and cardiac safety pharmacology. The specialty field of biomaterials, including drug eluting stents, is in its relative infancy and toxicologic pathologists need to have a working knowledge of the issues and processes in order to contribute to its evolution. Lastly, the expanding list of drug withdrawals due to functional cardiac liabilities and the ever increasing media attention to this area speaks for itself as to rationale for attending the session on cardiovascular safety pharmacology and modern risk assessment.

Continuing Education Courses

Sunday, June 19, 2005

CE 1

Immunostimulation – Maintaining the Balance
8:00 AM – 12:00 noon

The focus of this course will be various safety aspects of immunostimulatory agents, including vaccines and other biologics or small molecules intended to nonspecifically augment the immune response. Aspects that will be examined include the preclinical safety assessment of vaccines and aspects of the innate immune response, including some pertinent mechanisms and methods of monitoring immunostimulation.

CE 2

Dietary Supplements: Everything You Wanted to Know but Were Afraid to Ask
2:00 PM – 4:00 PM

Dietary Supplements have made news headlines during the past few years. They are relatively unregulated substances of various types with broad ranges of potential uses and misuses. For many of these substances, their biological activity and toxicology is poorly understood because preclinical and clinical studies are usually not required for sale and use in the USA. This CE course will explore the definitions and uses of

dietary supplements, the classification and applications of Chinese herbals medicines, medical research on dietary supplements sponsored by NIH and basic clinical and laboratory research of selected compounds.

Angiogenesis and Its Inhibition

Monday, June 20, 2005

Angiogenesis plays a critical role in embryogenesis as well as postnatal physiologic processes while dysregulation of angiogenesis has been implicated in a variety of pathologic processes such as carcinogenesis and intraocular neovascularization. In this session, the current understanding of angiogenic pathways will be reviewed, highlighting key signaling pathways. A variety of targeted approaches to stimulate and inhibit angiogenesis will also be discussed. Additionally, preclinical models of angiogenesis and some of the challenges in the development of angiogenesis inhibitors will be presented.

Chair: Anne Ryan, DVM, PhD, DACVP; Pfizer
Stephen Epstein MD, Cardiovascular Research Institute, Washington Hospital Center
Joseph Beyer DVM PhD-Senior Pathologist, Genentech Inc.

Local Delivery of a Cardiovascular Effect: Drug Eluting Stents and Other Devices

Monday, June 20, 2005

This session will show how the fast growing field of cardiovascular medical devices is designing standards for efficacy and safety assessment. Drug eluting stents are leading the charge and toxicologic pathologists will enjoy learning how the standards they have helped define for drug assessment are being translated to enhance the assessment of drug/device combination products. Histopathology based on MMA plastic techniques will be illustrated with practical examples. Animal models and their relevance to humans will be presented. The regulatory framework of medical device assessment will be laid out, particularly as it relates to up and coming combination products such as Drug Eluting Stents and their delivery systems.

Chair: Serge Rousselle, DVM, DACVP; Pathology Associates Division of Charles River Laboratories
Andrew Farb, MD, U.S. Food and Drug Administration
Robert S. Schwartz, MD, FACC, FAHA, Minneapolis Heart Institute Foundation

Vascular Injury in Animals and Humans: Pathogenesis and Biomarkers

Tuesday, June 21, 2005

The pathogenesis of chemically-induced vascular injury is an important and incompletely understood problem in toxicology and human medicine. A variety of marketed drugs and drugs in clinical development cause vascular injury in animals confirming a potential risk for humans where there is a significant and known background of pre-existing vascular disease. Due to the prominence of vascular disease in western societies, vascular biologists, pharmacologists, clinicians, toxicologists and pathologists have been attempting to elucidate mechanisms of drug-induced and spontaneous vascular injury in animals and humans for many years. Drug-induced vascular injury in animals is a topic of intense discussion and debate in the pharmaceutical industry as to its relevance to humans. In many pharmaceutical portfolios, a substantial number of candidate drugs are known to cause vascular injury in preclinical toxicology studies and a lack of understanding of the basic mechanisms by which drugs cause vascular injury in animals and humans, and the absence of specific and sensitive biomarkers have become significant barriers in the development of many classes of therapeutic agents. In the absence of adequate mechanistic data and valid biomarkers, regulatory agencies are still confronted with the need to determine human safety with empirical methods.

Chair: William Kerns, DVM, MS, DACVP; Pharma Consulting, Inc.
Heath Thomas; DVM, PhD, DAVCP, GlaxoSmithKline
Calvert Louden; DVM, PhD, DAVCP, AstraZeneca Pharmaceuticals
Eugenia Floyd; DVM, PhD DACVP, Pfizer

Paul Boor; MD, University of Texas Medical Branch, Dept of Pathology
Suzanne Kanaly DVM PhD, ICOS Corporatio

Preclinical Cardiac Safety Assessment: Relevance to Humans

Wednesday, June 22, 2005

In this session, the toxic effects of chemicals and biopharmaceuticals on the heart will be examined in both animals and humans. Anthracyclines are known cardiotoxins. An overview of the proposed mechanisms of anthracycline toxicity, including information generated by "-omics" studies, newer methods of detection of anthracycline toxicity, and possible means of ameliorating the toxicity, will be presented. Trastuzumab, a biopharmaceutical, provides significant benefit to patients. However, a risk for cardiac toxicity, most commonly presenting as a reversible asymptomatic decrease in left ventricular ejection fraction, was ide! ntified clinically. The current state of knowledge regarding trastuzumab-associated cardiac dysfunction will be discussed, including a discussion of preclinical and clinical work. Finally, sudden cardiac death is an issue that has received much greater attention in humans compared with animals. The issue of sudden cardiac death in humans unrelated to vascular disease will be explored, followed by an in depth discussion on molecular links to cardiac disease, the regulation of gene expression related to cardiac hypertrophy, and the phenotype of adaptive versus maladaptive responses associated with the progression of heart failure and sudden death.

Chair: Michael Leach, DVM, PhD, DACVP; Wyeth Research
Eugene Herman, PhD, Division of Applied Pharmacology Research, CDER, FDA
Noel Dybdal, DVM, PhD, DACVP, Genentech, Inc.
Renu Virmani, MD, CV Path
Y. James Kang, DVM, PhD, University of Louisville School of Medicine

Cardiovascular Safety Pharmacology and Modern Risk Assessment

Wednesday, June 22, 2005

Over the past decade, cardiovascular safety pharmacology has emerged as one of the most important and challenging areas of safety assessment. The heightened importance of this field spawned initially from a number of important product market withdrawals and development pipeline failures due to unanticipated functional cardiovascular effects, especially QT interval prolongation and the induction of fatal arrhythmias. It subsequently became clear that many of these drugs interacted with a cardiac K ion channel known as the HERG channel. As we have become more aware of this potential liability and have put in place more and better refined screening assays, it has become clear that cardiac safety is one of the most ubiquitous and challenging areas of modern risk assessment. This session will first introduce the audience to the field of modern safety pharmacology and the pertinent regulatory guidance. The rest of the session will then be focused on nonclinical and clinical assessment of cardiovascular safety assessment, with emphasis on QT liability. Overview presentations will then be followed by case studies that illustrate examples of risk management for potential cardiovascular safety issues.

Chair: Page Bouchard, DVM, DACVP; Archemix Corporation
Louis Kinter, PhD, AstraZeneca
Robert Hamelin, DVM, PhD, The Ohio State University
Philip Sager, MD, AstraZeneca
Vivek Kadambi, PhD, Millennium Pharmaceuticals

Cardiac Biomarkers: Clinical and Preclinical Use in Risk Assessment

Thursday, June 23, 2005

Cardiac toxicity presents significant challenges in the risk assessment of chemically induced cardiac changes. Reliable, practical biomarkers are a key ingredient in cardiac risk assessment and clinical

monitoring. The optimum application of cardiac biomarkers would allow seamless use both preclinically and clinically in a development plan. Unfortunately, this is generally not the current state of affairs in developing compounds with real or potential cardiac liabilities. To effectively use the biomarkers that are available, it is important to understand what potential assays could be used, the basis by which they work, the advantages and limitations of each assay, and whether the assay can be extrapolated from preclinical study results into a clinical setting. The goal of this session is to provide insight into the use of cardiac biomarkers currently available and under development. Speakers will address these biomarkers from both a clinical and preclinical perspective.

Chair: Ken Schafer, DVM, PhD, DACVP; Eli Lilly and Co.
Fred Apple, PhD, DABCC, Hennepin County Medical Center
Dana Walker, DVM, PhD, Diplomate, ACVP, Wyeth Research
Brian D. Hoit, MD, Case Western Reserve
Christian Badea, PhD, Duke University

Earn Continuing Education Credits

Attend the STP Continuing Education Courses and earn (for each course) 4 hours of AAVSB RACE continuing education credits under the category of medical/surgical jurisdictions. In addition, attendees of the STP Annual Meeting will earn 20 hours of AAVSB RACE continuing education credits.

NTP Satellite Symposium

The 2004 NTP Satellite Symposium will precede the meeting on Saturday, June 18 and will consist of *Pathology of the Immune System* organized by Dr. Robert R. Maronpot.

To register for the NTP Satellite Symposium, visit: www.toxpath.org

SOCIETY OF TOXICOLOGIC PATHOLOGY ACHIEVEMENT AWARD: CALL FOR NOMINATIONS

The Executive Committee is pleased to announce the Society of Toxicologic Pathology Achievement Award and call for nominations for this award. Information on the award is given below.

Award Requirements: This award is given by the Society of Toxicologic Pathology to a member in good standing who has played critical and influential roles in the area of toxicologic pathology over an extended period of time. Achievement may be demonstrated by a body of work in any or all of the following areas: scientific discovery, education, or regulatory standards.

Nomination: A call for nominations will be made by the STP Award Committee. Nominators must be STP members. The nomination will consist of a letter that highlights the candidate's achievement and influence in the area of toxicologic pathology and the candidate's CV. Two supporting letters from other STP members are required. Additional letters from non-STP members may be submitted. It is not necessary to submit the nominee's CV. Nominations will be held forward for 2 years.

Please forward the nomination electronically to stp@toxpath.org.

Evaluation: Nominations will be evaluated by the STP Award Committee which will consist of the President Elect and two members of the STP appointed by the EC. The STP will not necessarily award this honor to a member on an annual basis, but rather as it deems appropriate.

Award: The award will consist of a plaque and a $1000 check that will be presented at the STP Annual Meeting. No more than a single award will be given each year. The awardee will be recognized in *Toxicologic Pathology* in consultation with the Editor of *Toxicologic Pathology* (eg 1 page notice that includes a photograph). If appropriate, the awardee may be invited to give a lecture at the Annual Meeting or submit a manuscript or editorial for publication in *Toxicologic Pathology*. Award winners' names and contributions to toxicologic pathology will be maintained and listed on the STP website.

Timeline for Nomination: February 1, 2005.

Please forward the nomination and the supporting document to stp@toxpath.org.

Call for Abstracts:

April 1, 2005
Abstract Electronic Submission Deadline
STP is pleased to invite pathologist, residents, students, and all other attendees to submit abstracts for the poster presentation at the 2005 STO Annual Meeting. Visit www.toxpath.org to submit online. Approved abstracts will be presented at the Annual Meeting and published in the STP's journal, *Toxicologic Pathology*.

Promotional Opportunities.
Where will you find an audience where 43% of the attendees work in management and are the final decision-makers for the organization? At the Society of Toxicologic Pathology Annual Meeting in Washington, DC. The STP exhibit hall is 100% sold out; however, there are other ways to reach this influential niche market. Visit www.toxpath.org to learn more about promotional opportunities. a booth.

The ACVP/STP Coalition for Veterinary Pathology Fellows

by Gary L. Cockerell

A 2002 employer and training program survey confirmed a critical shortage of existing veterinary anatomic and clinical pathologists, and predicted the situation would worsen in the future due to continuing deficit in supply, increases in demand, and retirements in the current workforce (http://www.acvp.org/career/employsurv.pdf). In response to this shortage and to unite their efforts to increase the supply of veterinary pathologists, ACVP Council and STP Executive Committee recently created "The ACVP/STP Coalition for Veterinary Pathology Fellows."

The goal of the Coalition is to create 5 new training positions in the first year and a total of 15 positions after three years. These positions will be funded by industry and private foundations, and will support three years of residency and/or PhD graduate research training in anatomic or clinical pathology, including stipend, tuition, health benefits, travel and educational supplies. Positions will be awarded to academic training institutions based on competitive review of proposals submitted in response to a Request for Applications issued by the Coalition. A close interaction will be established between successfully funded training programs, fellows and sponsors to enhance the training experience, and to more effectively cross-communicate programmatic goals and objectives. Coalition Fellows will be expected to complete the ACVP Certification Examination and/or their PhD degree within two years of the end of funding and to pursue careers in either veterinary anatomic or clinical pathology, but otherwise will have no pay back obligation.

General oversight of Coalition activities will be provided by ACVP Council and STP Executive Committee. Strategic leadership will be provided by a Board of Governors, consisting five members each of the ACVP and STP, and current Presidents of both organizations as ex officio members. Inaugural ACVP Board members are Drs. Reid Patterson, Chair (Reid Patterson Consulting), Willie Reed (Mich St Univ), John Shadduck (Shadduck Consulting), John Strandberg (Johns Hopkins Univ) and Mary Anna Thrall (Colo St Univ); inaugural STP Board members are Drs. Wanda Haschek-Hock (Univ of Ill), Vince Meador (Eli Lilly), Jim Moe (Myrtle Beach, SC), John Robertson (Virginia Tech) and Anne Ryan (Pfizer-PGRD). Dr. Gary Cockerell (Cockerell Alliances) will serve as Director and will be responsible for implementation and administration of the Coalition. Potential sponsors and training institutions can expect to receive additional information in the near future as soon as final administrative details are completed.

In summary, the Coalition represents a unique partnership between the ACVP and STP that will result in multiple advantages and mutual benefits for all participants; it will (1) increase the supply of veterinary pathologists, (2) provide a unified mechanism for ACVP/STP-endorsed solicitation and distribution of funds to train veterinary pathologists, and (3) provide a conduit for enhanced interaction between academic and industrial veterinary pathologists.

Exhibit List:

Ani Lytics, Inc
Aperio Technologies, Inc
Battelle Toxicology Services
Charles River Laboratories Discovery and Development Services
CTBR (A Member of the Charles River Laboratory Group)
EPL, Inc.
Huntingdon Life Sciences
IDEXX Preclinical Research Services
Instem LSS Ltd
Inveresk Research
Lifeblood Medical, Inc.
MRPath
National Library of Medicine
Olympus America Inc. - S.E.G.
Paradigm Genetics, Inc.
Pathology Data Solutions, Inc.
RTPA
Scienteur
Scimagix™ Inc.
SNBL USA, LTD.
Taylor & Francis Publishers
Thermo Electron Corporation
Trestle Corporation
Xybion Medical Systems

2004 October Executive Committee Highlights

Incorporated the 2005 Committees' budget requests into the approved 2005 Society budget.

Established an Award Committee to review and recommend the winner of the Achievement Award.

Confirmed the 2005 Annual Meeting registration fees and established a non-member academic/government registration fee based on recommendations from the Membership Committee.

Approved the 2005 officer slate as recommended by the Nominating Committee.

Selected STP representatives to serve on the ACVP/STP Coalition Board of Governors.

Fundraising Committee Report:

The Fundraising Committee is in the process of contacting potential sponsors for the 2005 Annual Meeting to be held in Washington, DC. In addition, the Committee is also contacting organizations to renew or establish new Organizational Membership within the Society. It's through the continued support of organizations that STP is able to achieve its mission and goals to play an intricate role in fostering training and recognition of toxicologic pathologists.

The Fundraising Committee needs the support of all Society members to solicit funds for the Society. General Organizational Membership dues finance the general administration of the Society and also contribute to the reduced Annual Meeting membership registration fees. Even though the Washington, DC is a more expensive city than Salt Lake City for hosting a meeting, the Society has been able to hold the registration fees at the same level as 2004 for the membership.

A list of Organizational Membership Benefits are available on the STP web site. If you have any questions or recommendations. please contact STP Headquarters at (703) 438-7508.

STP Online Membership Database

Keep Up To Date in Real Time….
Has your e-mail address changed lately? Or have you changed employers recently? The online membership directory allows you the option to change your contact information as many times as you want and the results will appear in the online membership database in real time. Previously the STP membership database was only updated once a quarter.

Please contact the STP Headquarters (stphq@toxpath.org) if you have any difficulty accessing the Members Only section of the STP web page.

New *Toxicologic Pathology* Editor in Chief Vision for the Journal

James Klaunig

I am honored to have been given the opportunity to serve as the new editor of *Toxicologic Pathology*. I plan to continue the high quality and standard of excellance established by the previous editors of *Toxicologic Pathology* and am indebted to Bob Maronpot, Stephanie Dickinson, and Clarissa Russell Wilson in helping to make my transition to the Editor in Chief painless so far. My goal for *Toxicologic Pathology* is ambitious. With the help of the Editorial Board and your help, I hope to make *Toxicologic Pathology* the most respected Journal in the fields of Toxicology and Pathology - being the first choice for publication by scientists in the toxicology and pathology. The Journal should serve as a conduit for the society's membership to publish their best work and should serve as the non-members window to the Society.

Several changes will be occurring in the near future. First, in cooperation with Taylor & Francis, we will adopt and implement Scholar One/Manuscript Central for manuscript submission, manuscript handling, and manuscript review. Scholar One is a web based system that allows authors, editorial board members, and reviewers immediate, password protected access to manuscripts (24/7) through the internet. With the implementation of Scholar One, I plan to increase the number of associate editors for the journal since the adoption of Scholar One will allow the associate editors to directly make reviewer assignments and track reviewer and author responses. We are also in discussion with Taylor & Francis (pending EC approval) to increase the number of issues from the current 6 per year to 9 per year; making the symposium papers the first issue of each year. And finally, I plan to include an invited, timely review article in each issue. I look forward to an exciting tenure as Editor and welcome your suggestions and comments.

Non-Members of Education Board:

Cindy Afshari, PhD
Amgen Inc.
One Amgen Center Dr.
Mailstop 5-1-A
Thousand Oaks, CA 91320-1799
Phone: 805-447-3537
Fax: 805-499-4687
Pager: 805-359-2685
email: cafshari@amgen.com
Term: 1/04-12/06

Robert D. Cardiff, MD, PhD
Center for Comparative Medicine
University of California, Davis
98 County Road and Hutchison Drive
Davis, CA 95616
Phone : 530-752-2726
Fax : 530-752-7914
Email: rdcardiff@ucdavis.edu
Term : 01/03-12 /05

Robert Chapin, PhD
Pfizer Inc.
Eastern Point Road, MS 8274 1336
Groton, CT 06340
Phone: 860-441-0571
Fax: 860-715-3577
Email:
Robert_e_chapin@groton.pfizer.com
Term: 1/04-12/06

Kunitoshi Mitsumori, D.V.M., Ph.D.
Faculty of Agriculture
Tokyo University of Agriculture and Technology
3-5-8 Saiwai-cho, Fuchu-shi,
Tokyo 183-8509 Japan
Phone/Fax: 042-367-5771
E-mail: mitsumor@cc.tuat.ac.jp
Term: 1/04-12/06

Alexander Yu. Nikitin, MD, PhD
Department of Biomedical Sciences
Cornell University
T2 014A VRT Campus Road
Ithaca, New York 14853-6401
Phone: 607-253-4347
Fax: 607-253-4212
Email: an58@cornell.edu
Term: 1/04-12/06.

Lorenzo Tomatis, MD
Cave 25/r
334011 Aurisina (Trieste)
Italy
Phone: 39-0402-00284
Fax: 39-0402-25049
Email: ltomatis@hotmail.com
Term: 1/04-12/06

President's Report:

Season's Greetings to all! In this report I wish to highlight the accomplishments made toward achieving the goals in our strategic plan over the last six months. Just as a reminder, our clients are (external) regulatory authorities and (internal) our members, and our vision is to be *an international leader for improvement of human and animal health using an interdisciplinary scientific approach based in pathology and toxicology*. I am pleased to tell you that we have made excellent progress on our **recruitment**, **advocacy**, **globalization**, and **collaboration** goals. It is important to note that these accomplishments have occurred in less than six months. I will highlight a few of the developments that have occurred since we last met in Salt Lake City.

The STP Committees presented individual work plans for the 2004-2005 year, and after reviewing these plans, the EC was able to fulfill most of the funding requests. The requests were reflected in the budget for 2005, which was passed during the October EC meeting in Montreal. If you feel that you are being left out and wish to contribute, there is ample opportunity to volunteer to help the Society develop over the next few years. Please contact the committee chairperson, if you are interested. The names of committee chairs can be found on our web page at www.toxpath.org.

The following accomplishments have been made since the annual general meeting in Salt Lake City:

1. ***Recruitment:***
    a. The ACVP-STP coalition has been formalized and a contract has been signed with **Gary Cockerell**, who is the presiding Director of the coalition. The coalition has a Board of Governors with equal membership from the ACVP and STP and will be chaired by **Reid Patterson**. The Board of Governors has the following representation from the STP: **Wanda Haschek-Hock**, **Jim Moe**, **Vince Meador, John Robertson** and **Anne Ryan** and from the ACVP **Reid Patterson**, **Willie Reed**, **John Strandberg**, **John Shadduck**, **Mary Anna Thrall.** Both the Presidents of the ACVP and STP are *ex officio* members. The coalition had its first meeting at the ACVP general meeting in Orlando in November 2004. The next task of the Board of Governors is to develop plans and criteria for all aspects of the coalition's work. The goal at present is to raise sufficient money to fund five extra training positions at approved institutions.
    b. **Recruitment Committee** – contact **Kevin McDorman** has been active in the following areas:
        i. Developing a brochure to promote awareness of the STP to other scientists;
        ii. Creating a Career Development Program for the Annual General Meeting in Washington DC, 2005;
        iii. Writing an advertisement and submitting it to the Winter/Spring 2005 Edition of Career Insights MD, in an effort to recruit non-member practicing toxicological pathologists, more MD

pathologists, and non-classically trained individuals who work in the field of Toxicologic Pathology;
iv. Developing a letter to be sent to all new ACVP diplomats; and
v. During the ACVP meeting, members of the STP talked with most students present, espousing the benefits of toxicologic pathology and the STP. These students will receive a follow-up letter or call during our "get a new member" campaign.

c. **Membership Committee** - has been active in the following areas:
   i. Developing an Annual Meeting registration fee for non-member academic and government attendees;
   ii. Constructing a non-member registration plan to entice non-members to become members;
   iii. Making several recommendations to the EC for enhancing the value of membership; and
   iv. Evaluating methods to enhance membership retention.

d. **Executive Committee** – has created a new committee called the **Awards Committee.** The purpose of the Awards committee is to recognize those individuals in our Society who have made outstanding contributions to the field of toxicologic pathology during their career.
   i. The first award will be given during the 2005 Annual General Meeting in Washington, DC, 2005;
   ii. Nominations for this award should be forwarded to **Wanda Haschek-Hock,** who chairs this committee; and
   iii. If the membership believes that other awards should be considered, please contact the committee with your suggestions.

2. ***Advocacy:*** Advocacy has occurred in the following areas
   a. **Continuing Education Committee (CEC)** – Education is one of our core outreach programs.
      i. Educating domestic and international regulatory agencies continues and *volunteers are welcome to assist in this program*. The Society has been asked to produce a course for the FDA, which requires about a one-day commitment for each "module." Modules will contain basic organ responses, etc., and how to handle difficult regulatory questions. One module will be given every three weeks during the following times 10:00 – 12:00 and 12:30 – 14:30. For further information, or to volunteer, please contact **Paul Howroyd**;
      ii. The Scientific Program has been planned and is now well underway. If you would like to help, contact **Rich Westhouse**;
      iii. The Society is collecting an archive of presentations given by members, so that other STP members can use our materials for outreach presentation. For further information contact **Susan Hart** or **Clarissa Russell Wilson**;

iv. The CEC has arranged for the STP to sponsor for "Chemically-induced Vascular Injury in Animals and in Humans." For more information please contact **Jerry Ward**; and
v. **Amy Brix** is organizing the Continuing Education component of the 2005 Annual Program.

b. **Continuing Education Committee and SRCP Committees** –
   i. Are working on a regulatory session to be held during the Annual Meeting, so as to attract our clients attract to the Annual General Meeting in DC, 2005; and
   ii. STP members are planning delivery of another course on "Pathology for Non-Pathologist" during the **American College of Toxicology (ACT)** conference in 2005. To help with this task, please contact **Cynthia Shackelford**;

c. **Public Relations Committee** – is currently developing a booth for taking to conferences so as to promote the Society. Contact **Mark Mense** to lend a hand with these efforts. This committee is crucial to the advocacy goal; therefore, if you could possibly help with this effort, your Society will benefit!

d. **Internet Committee** –
   i. Is updating the look of the web page and simultaneously, incorporating the strategic plan for ready reference on our web site; and
   ii. Requesting, "What 's your Diagnosis?" pictures and troublesome data sets. Contact **Laura Dill Morton**.

e. **Science and Regulatory Pathology Committee** - continues to develop Best Practices Guidelines for regulators.
   i. The latest best practice document is entitled *"Best Practice Guideline for the Routine Pathology Evaluation of the Immune System."* This document is open for comments on clarity. Please forward any comments to **Rick Perry** of the SRPC regarding this document;
   ii. The *"Best Practice Guideline for the Routine Pathology Evaluation of the Ovary"* is awaiting comments from the FDA. Any comments regarding this document should be forwarded to **Karen Regan.**
   iii. The SPRC has commented on the "Canadian Draft Guidance on Preclinical Detection of Hepatotoxicity." The next revision of the Draft Guidance document will become available in early 2005. For comments please contact **Vince Meador** or **Laura Boone**;
   iv. Work continues on electronic data storage under GLP regulations: contact - **Darrell Tuomari**

f. There is a general interest in updating the **System of Standard Nomenclature for Diagnostic Criteria**. Although this task will need planning and coordination by the SRPC, it is hoped that an individual from the Society will take on the job as coordinator for the revisions.

Please contact **Glenn Elliott**, or any other member of the SRPC for further information.

g. **Nominating Committee** - has nominated a variety of candidates for the various offices. Ballots will be available shortly.

h. Journal -

i. The **Journal Transition Team (JTT)** has completed the transition of the journal from **Bob Maronpot** to **Jim Klaunig** as editors. **Stephanie Dickinson** will continue working with Jim, and Bob will continue to oversee quality of images. The JTT has now dissolved;

ii. A new committee – **Journal Committee** – has been established so as to improve contact between the EC and the Journal and non-editorial issues that may affect the journal and the Society. For more information please contact **Peter Mann.**

iii. The Journal has moved from six to seven issues printed yearly;

iv. E-Publishing is currently being implemented, meaning that citations for articles published will be available following acceptance of the manuscript, before the hard copy is printed;

v. **Jim Klaunig** is starting the use of Scholar – one, an online review system that decreases extra work and increases collaborative activities among associate editors and reviewers.

3. ***Globalization:***

a. The STP continues to be a member of the **IFSTP**;

b. STP has joined **IUTOX**;

i. We are looking forward to sponsoring and presenting a Satellite Program of "Pathology for Non-Pathologists" and "Addressing the Low Incidence of Rare Tumors in Rodent Toxicology Studies" the next International Congress of Toxicology (**ICTXI**) meeting in 2007 in Montreal – contact **Paul Howroyd**; and

c. A "grass roots" collaborative effort among individuals in the STP and other countries has begun:

i. For the first time we have STP members based internationally working on committees – **Bob Thoolen** (Netherlands) and **Toshimi Usui** (Japan).

d. **Liaison Committee** and **CEC** - working with other organizations such as **ACT** to host continuing education sessions for fellow scientists.

4. ***Collaboration*** continues with the ACVP, IFSTP, IATP, SOT, ACT, and others.

a. Collaboration has improved with the ACVP;

b. Initial discussions have been made regarding the coordination of position papers, advocacy and recruitment; and

c. The STP continues to expand its collaborative activities with Academia, Government and Industry.

I wish to thank all who have been involved in these accomplishments. If anyone else thinks that they could lend a hand, even for a short time, please contact the committee chairs, Clarissa Russell-Wilson, or me. If everyone lends a hand we will be able to get closer to our objectives!

Now it is time for a break over the holidays. Let's rest for a bit, then let's get back to moving the Society forward, showing the importance of toxicologic pathology in regulatory decision making.

Colin Rousseaux
President

Promotional Opportunities:

Where will you find an audience where 43% of the attendees work in management and are the final decision-makers for the organization? At the Society of Toxicologic Pathology Annual Meeting in Washington, DC. The STP exhibit hall is 100% sold out; however, there are other ways to reach this influential niche market. Visit www.toxpath.org to learn more about promotional opportunities. a booth.

Job Posting Reminder

Social Events:

Welcome Reception – Sunday, June 19, 2005 5:00 PM – 6:30 PM
Come and enjoy a relaxing evening mingling with friends and colleagues. Admission to the Welcome Reception is included in the member, non-member, student and spouse/guest registration fees. Light hours d'oeuvres will be served and a drink ticket. Attire will be causal.

Student Reception – Sunday, June 19, 2005 6:00 PM – 7:00 PM
This will be a fun opportunity to meet fellow students, and interact with the scientists representing al facets of the Society as you discuss your future and the various career paths available to you. This function has been the highlight of past meetings for many students. Come and take advantage of the unique networking opportunity.

President's Gala Reception – Wednesday, June 22, 2005
Admission to the President's Gala Reception is included in the member, non-member, student and spouse/guest registration fees. Hors d'oeuvres will be served and each attendee will receive two drink tickets. Attire will be business casual.

Student Travel Award:

Purpose

Travel Awards are available to Graduate Students for participation in the 24th Annual Symposium of the Society of Toxicologic Pathology to be held in Washington, DC 19-23, 2005 Listed below are the specifics for the 2005 Student Travel Awards competition:

- Recipients will be awarded a grant to defray registration, travel and lodging costs associated with attendance at the Annual Symposium.
- Recipients will be honored at an awards ceremony during the business meeting.
- Recipients will receive a student membership in the Society of Toxicologic Pathology for one year.

Eligibility

- Nominees must currently be enrolled in a full-time veterinary medical or medical graduate degree or residency program in pathology/toxicology and have a demonstrated interest in toxicologic pathology. Nomination of candidates who have recently completed (within 12 months) a graduate and/or residency program in toxicologic pathology will also be accepted.

Nomination Procedure

- The student's faculty advisor must submit a letter of nomination summarizing qualifications of candidate and a curriculum vitae of candidate with a statement of career goals in toxicologic pathology.
- Submission of an abstract for a poster presentation at the Annual Meeting in the area of toxicologic pathology is encouraged but not required.

Deadline

- Nomination materials should be submitted by April 1, 2005. Winners will be notified shortly thereafter.

Mailing Address

- Send all nominations to the Society of Toxicologic Pathology, 1821 Michael Faraday Drive, Suite 300, Reston, VA 20190.

A Tribute to Robert R. Maronpot on his retirement as editor of Toxicologic Pathology:

I have known and worked with Dr. Maronpot for more than 20 years. He is an astute manager and a fearless leader who aggressively supports his staff. He works efficiently and tirelessly to promote the National Institute of Environmental Health Sciences (NIEHS), the National Toxicology Program (NTP) and the discipline of toxicologic pathology. As many of us age and stick with familiar areas, Bob continues to break new ground. I was delighted that Dr. Maronpot was selected and accepted the editorship of Toxicologic Pathology. Dr. Maronpot's expertise and interest in images, photography, electronic transfer of data and digital pathology all seemed essential for our journal to move forward. I admit that I wondered where he would find the time with so many existing commitments including mentoring young (and old) pathologists, assuring that the pathology needs of the NTP were met and providing support for the intramural scientists at the NIEHS.

My fears were superfluous because as is typical for Bob, he has performed admirably as editor. Bob has always had an interest in time management; his talent in this area coupled with his assembly of an excellent team of associate editors resulted in timely publication of manuscripts of the highest professional standard.

Bob has used his position as editor to inform the readers through invited reviews, guest editorials and his own comments that have appeared in the journal. Dr. Maronpot has embraced new technology with an increase in the number of article on immunohistochemistry, mutational analyses of rodent tumors, transcriptome analyses of rodent tissues and magnetic resonant imaging to mention a few areas. Dr. Maronpot retains an enthusiasm for emerging technologies and how they can assist the pathologist in understanding the complete picture.

Above all, Bob is an educator and quite creative. As part of his work with STP, he created and made freely available CD's of images of specific rodent at many of the recent annual meetings. Bob conducted several highly educational pathology working workshops at the last few Society meetings. The images of lesions were available on the web prior to the meeting for review, the lesions were then presented at the workshop, where all participants electronically registered their diagnosis after reviewing the specific lesion and an electronic tally recorded the diagnoses as they were made. The resulting list of diagnoses stimulated further discussion and an opportunity for each to re-assess their diagnoses. The final tally provided each pathologist with valuable feedback from colleagues and served as excellent teaching tool. Developing a set of lesions for each workshop and the images to go with it is a trivial task; however, this workshop has become quite popular, Dr. Maronpot and his colleagues seemed destined to continue it for some time.

For many years, Dr. Maronpot has had a positive and long lasting effect on the NIEHS and on pathologists working with him. He now has had a broader constructive impact on pathologists through improving the quality of our journal; I can only anticipate where he

will spend his talents once handing this task of editor is completed. I: am confident that pathologists in general and our Society in particular, will continue to benefit from Dr. Maronpot's vast talents.

Gary A Boorman, DVM, PhD
NIEH

Remember To Vote:

Full members of the Society should take advantage of their member benefit to vote for Vice President and Councilor. For 2005, there are four open seats on the Executive Committee. The candidates for President-Elect include Stuart Levin, Gerry Long and Ricardo Ochoa. The candidates for the Secretary/Treasurer are Jeff Engelhardt and Karen Regan. The candidates for two Councilor seats include: Page Bouchard, Noel Dybdal, Robert Sills and Matthew Wallig. Please visit www.toxpath.org to view the ballot and to cast your vote or contact STP Headquarters for a paper ballot. The deadline casting your vote is April 1, 2004.

Get Involved in STP

STP is always seeking interested members to become more involved in the Society through Committee participation and/or to serve as a liaison to a sister society. Volunteer to be a member of one of the following committees: annual symposium, continuing education, external affairs, fundraising, internet, membership, nominating, scientific and regulatory policy. Please send an e-mail message to clarissa@toxpath.org stating your interest.